抗PD-1抗体一线免疫治疗结外NK/T细胞淋巴瘤:一项回顾性研究
该回顾性研究分析了107例初诊结外NK/T细胞淋巴瘤(ENKTL)患者,比较一线抗PD-1抗体诱导治疗与抗PD-1抗体联合门冬酰胺酶为基础的化疗(免疫化疗)的疗效与安全性。免疫化疗组总缓解率和完全缓解率均高于免疫诱导组(86.11% vs 62.86%和72.22% vs 52.29%,p=0.013),且免疫化疗是更长无进展生存期(PFS)的独立预后因素(p<0.001)。治疗前CD4/CD8比值>0.83与更好的缓解和更长PFS显著相关。
要点
- 免疫化疗组总缓解率86.11% vs 免疫诱导组62.86%,完全缓解率72.22% vs 52.29%(p=0.013)。
- 免疫化疗是更长PFS的独立预后因素(p<0.001)。
- 治疗前CD4/CD8比值>0.83与更好的缓解和更长PFS显著相关,且治疗后EBV血浆拷贝数下降更显著。
核心结论
- 抗PD-1抗体治疗在初诊ENKTL患者中显示出有前景的结果。
- 治疗前CD4/CD8比值评估似乎可行,用于识别抗PD-1抗体治疗的应答者。
研究设计与样本
- 回顾性分析107例初诊ENKTL患者的临床数据。
- 患者接受一线抗PD-1抗体诱导治疗或抗PD-1抗体联合门冬酰胺酶为基础的化疗(免疫化疗)。
主要发现
- 免疫化疗是更长PFS的独立预后因素(p<0.001)。
- 免疫化疗组总缓解率高于免疫诱导组(86.11% vs 62.86%),完全缓解率亦高于免疫诱导组(72.22% vs 52.29%),p=0.013。
- 治疗前CD4/CD8比值>0.83与接受一线抗PD-1抗体治疗的ENKTL患者更好的缓解和更长PFS显著相关。
- CD4/CD8比值>0.83的患者治疗后EBV血浆拷贝数下降更显著。
- PD-L1表达与更好的缓解和PFS相关,而血浆IL-6、IL-10和IFN-γ升高与不良预后相关。
关键数值与推荐
- 免疫化疗组总缓解率86.11% vs 免疫诱导组62.86%(p=0.013)。
- 免疫化疗组完全缓解率72.22% vs 免疫诱导组52.29%(p=0.013)。
- 免疫化疗作为更长PFS的独立预后因素,p<0.001。
- 治疗前CD4/CD8比值>0.83与更好的缓解和更长PFS显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-PD-1 antibody has shown certain effects in patients with newly diagnosed extranodal NK/T-cell lymphoma (ENKTL). Here, we evaluated the clinical efficacy and safety of first-line anti-PD-1 antibody for the treatment of patients with ENKTL and explored biomarkers for treatment response. The clinical data of 107 patients with newly diagnosed ENKTL were retrospectively analysed. Patients received either first-line anti-PD-1 antibody induction treatment or anti-PD-1 antibody combined with asparaginase-based chemotherapy (immunochemotherapy). We found that immunochemotherapy was an independent prognostic factor for longer PFS (p < 0.001). The overall response rate and complete remission rate of immunochemotherapy group was higher than immunotherapy induction group (86.11% vs. 62.86% and 72.22% vs. 52.29%, respectively, p = 0.013). We also observed pretreatment CD4/CD8 ratio >0.83 was significant associated with better response and longer PFS in ENKTL patients received first-line anti-PD1-antibody. Plasma copy number of EBV decreased more significantly in patients with CD4/CD8 ratio >0.83 after treatment. PD-L1 expression was associated with better response and PFS, while elevated plasma IL-6, IL-10 and IFN-γ were associated with poor prognosis. Anti-PD-1 antibody treatment showed promising results in newly diagnosed ENKTL patients. The assessment of pretreatment CD4/CD8 ratio in ENKTL seems feasible for identifying responders to anti-PD-1 antibody treatment.
引用
- Wang X, Wen L, Liao J, et al. First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma: A retrospective study. Br J Haematol. 2023. PMID: 37394245. doi:10.1111/bjh.18957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。